Tempus AI, Inc. (TEM) Total Return:-29.95%(TTM)
Over the latest trailing 12-month period, Tempus AI, Inc. (TEM)'s total return cagr is -29.95%. The comparable SPY value is +22.75%. Year-to-date total return is -16.02%. Total return includes price appreciation and reinvested dividends.
Growth of $10,000 in TEM
$12,320
(1.2x return)
Invested on Jun 14, 2024
Growth of $10,000 in SPY (S&P 500)
$13,676
(1.4x return)
Invested on Jun 14, 2024
Hypothetical Growth of $10,000
This chart illustrates the cumulative performance of a hypothetical $10,000 investment. It assumes that all dividends paid by both the stock and SPY are reinvested in additional shares on the payment date, showing the true long-term compounding impact of distributions.
Recent Performance Indicators
YTD Total Return
-16.0%
1-Year Total Return
-29.9%
Current Dividend Yield
0.00%
Price CAGR vs. Total Return CAGR
Compound Annual Growth Rate (CAGR) is shown below. The difference between price CAGR and total return CAGR is the compound contribution of dividends reinvested.
| Holding Period | Price CAGR | Total Return CAGR | Dividend Addition |
|---|---|---|---|
| 1 Year | (29.9%) | (29.9%) | — |
| 3 Years | — | — | — |
| 5 Years | — | — | — |
| 10 Years | — | — | — |
| 15 Years | — | — | — |
| 20 Years | — | — | — |
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky